Discover trends, market shifts, and competitive outlooks for the crohn’s disease (cd) treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Crohn’s Disease (CD) Treatment Market Expected to Grow Between 2025 And 2029?

The market size for Crohn’s disease (CD) treatment has seen significant growth in the recent past. It is predicted to expand from $11.76 billion in 2024 to $12.38 billion in 2025, projecting a compound annual growth rate (CAGR) of 5.3%. The previous growth trends have been the result of increasing cases of Crohn’s disease, heightened disease awareness, initiatives by the government, and lifestyle changes.

Significant expansion is anticipated in the Crohn’s disease (CD) treatment market size within the forthcoming years, with a projected growth to $15.06 billion in 2029 at a compound annual growth rate (CAGR) of 5.0%. This predicted growth during the forecast period can be associated with the rising demand for combination therapies, the increasing use of biologics, and financial investments in the research and development of Crohn’s disease (cd) treatments. The period’s major trends include the development of biologic drugs, the introduction of innovative products, the advancement of diagnostic tools, and the uptake of biosimilars.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Which Primay Drivers Are Accelerating Growth in the Crohn’s Disease (CD) Treatment Market?

The growth of the Crohn’s disease (CD) treatment market is anticipated to be propelled by the escalating prevalence of inflammatory bowel diseases. Inflammatory bowel disease (IBD) is a collection of ongoing inflammatory conditions, primarily targeting the gastrointestinal (GI) tract. The treatment of Crohn’s disease (CD) provides symptom relief, reduces inflammation, encourages remission, and enhances the overall life quality for individuals afflicted with chronic inflammatory bowel disease. For instance, in September 2023, data from the United States National Library of Medicine, a medical library based in the US, revealed that in Canada, the rate of inflammatory bowel diseases (IBD) in 2023 was estimated to be around 30 per 100,000 person years, with future projections hinting at a steady growth rate of approximately 0.58% per annum. By 2023, the incidence of IBD in Canada had reached around 825 per 100,000, with predictions suggesting this might escalate to 1.1% of the population by 2035. Accordingly, the escalating prevalence of inflammatory bowel diseases is driving the Crohn’s disease (CD) treatment market forward. The Crohn’s Disease (CD) Treatment Market growth is driven by the increment in clinical trials. The rising number of clinical trials is expected to foster the development of the Crohn’s disease treatment market. They are crucial for verifying the safety and effectiveness of these innovative therapies, and their success paves the way for regulatory approvals and the emergence of new treatment alternatives for CD patients. The pursuit for more potent Crohn’s disease treatments stimulates clinical trials, with both patients and healthcare providers yearning for improved outcomes and reduced side effects, spurring research and development initiatives. For instance, in September 2023, the University of California, a public land-grant research university based in the US, indicated that there are currently 17 ongoing clinical trials at UCSF specifically focusing on the use of vedolizumab and oral ozanimod, with goals to evaluate the long-term effectiveness of mirikizumab for pediatric patients suffering from Crohn’s disease or ulcerative colitis. Consequently, the surge in the number of clinical trials is expected to stimulate the growth of the Crohn’s disease treatment market in the future.

Which Primary Segments of the Crohn’s Disease (CD) Treatment Market Are Driving Growth and Industry Transformations?

The crohn’s disease (CD) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Other Drug Types

2) By Route of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores

Subsegments:

1) By Antibiotics: Metronidazole, Ciprofloxacin, Rifaximin

2) By Amino Salicylates: Mesalamine, Sulfasalazine

3) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone

4) By Immunomodulators: Azathioprine, Mercaptopurine, Methotrexate

5) By Other Drug Types: Biologic Therapies, Janus Kinase Inhibitors, Small Molecules

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12902&type=smp

Which Regions Are Key Players in the Growth of the Crohn’s Disease (CD) Treatment Market?

North America was the largest region in the Crohn’s disease (CD) treatment market in 2024. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Crohn’s Disease (CD) Treatment Industry Dynamics?

Leading enterprises in the Crohn’s disease (CD) treatment sector are integrating fresh technologies like IBDSENSE to maintain their market standing. For example, in March 2023, the Scotland-based interdisciplinary hub, The IRR Chemistry Hub, crafted IBDSENSE. The aim of this technology is to enhance the diagnosis and monitoring of inflammatory bowel disease, including Crohn’s disease, through non-invasive techniques. This project leverages fluorescence-based technology to gauge the enzyme activity of Granzyme B (GzmB) in patient biosamples. The goal of this technology is to refine the patient’s experience and their treatment options.

View the full report here:

https://www.thebusinessresearchcompany.com/report/crohns-disease-cd-treatment-global-market-report

What Parameters Are Used to Define the Crohn’s Disease (CD) Treatment Market?

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn’s disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12902

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model